Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205635 | 0.79 | — | — | |
| SCHEMBL5208825 | 0.76 | HMGCR (0.31) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL5208056 | 0.75 | LMNA (0.34) | ALDH1A1 | |
| SCHEMBL4145027 | 0.74 | TDP1 (0.35) | ALDH1A1 | |
| SCHEMBL12083942 | 0.72 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL16153654 | 0.72 | PIN1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL5206247 | 0.72 | POLB (0.31) | — | |
| SCHEMBL5206437 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL4162184 | 0.70 | CES2 (0.41) | ALDH1A1TSHR | |
| SCHEMBL10016683 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2021-12-07 | — | — | US | disclosed |
| EP-3135110-B1 | 1,7-DIARYL-1,6-HEPTADIEN-3,5-DION DERIVATIVES, METHODS OF MAKING AND USING THE SAME | TRIOPTOTEC GMBH (DE) | 2019-07-10 | — | — | EP | disclosed |
| US-20180272013-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄT SALZBURG (AT) | 2018-09-27 | — | — | US | disclosed |
| CN-108347927-A | 1,7- diaryl -1,6- heptadiene -3,5- derovatives, preparation method and use | 雷根斯堡大学临床中心 | 2018-07-31 | — | — | CN | disclosed |
| WO-2017032892-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODCUTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2017-03-02 | — | — | WO | disclosed |
| EP-3135110-A1 | 1,7-DIARYL-1,6-HEPTADIEN-3,5-DION DERIVATIVES, METHODS OF MAKING AND USING THE SAME | Universitätsklinikum Regensburg (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-0958292-B1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-6165944-A | 4-(3-heterocyclyl-1-benzoyl) pyrazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0777658-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| EP-0499266-B1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-07-10 | — | — | EP | disclosed |
| WO-1996005179-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5352659-A | Polypeptide; hypotensive agents | TAKEDA CHEMICAL INDUSTRIES (JP) | 1994-10-04 | — | — | US | disclosed |
| US-5306808-A | Endothelin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0547317-A1 | Endothelin antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0499266-A1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0470256-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1991013089-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | HMGCR 984/4885CHRM1 4364/4885TBXA2R 1338/4885 |
| US-20180272013-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | HMGCR 984/4885CHRM1 4364/4885TBXA2R 1338/4885 |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | HMGCR 984/4885CHRM1 4364/4885TBXA2R 1338/4885 |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | HMGCR 984/4885CHRM1 4364/4885TBXA2R 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.